FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 441 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials December 6, 2023 Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side... October 4, 2021 ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery February 28, 2024 A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence November 19, 2020 Load more HOT NEWS Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm Speaking a thousand words – how a cancer image collection is... How serendipity sent this oncologist in search of a cure for... The Growths On This Woman’s Lips Are A Sign That She...
